on behalf of the EORP-AF Investigators ABSTRACT OBJECTIVES This study sought to compare age-related differences in presentation, treatment, and outcome of atrial fibrillation (AF) in a wide cohort of European subjects.
A trial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a prevalence and incidence that increase with age (1) (2) (3) .
From 2010 to 2060, the number of subjects age $55 years with AF in the European Union is expected to more than double, resulting in a rise of affected population from 8.8 to 17.9 million (4). This is consistent with projections for the United States, where 5.6 million subjects (age >80 years in more than 50% of cases) are expected to present AF in 2050 (5) .
The importance of AF in older patients goes beyond its epidemiological impact, being closely linked with increased mortality (6,7) and a higher burden of comorbidities that are common in advanced age, such as stroke (8) , chronic heart failure (CHF) (9) , and dementia (10) .
It is therefore important to evaluate how AF is managed at older ages. Despite observational studies (5, 11) and trials (12) that have proven that benefits from oral anticoagulants (OA) extend to the oldest segments of AF population, real world data consistently show that prescription rate of OA is inversely related to age. (13) , showing that older patients with AF were less often referred to a cardiologist and less adequately studied and treated (14) . Even when OA are prescribed, advanced age is an independent predictor of reduced adherence (15) or premature interruption (16) . An increased awareness of the importance of OA in the elderly (17) , and an update of the ESC AF guidelines specifically addressing the management of OA with inclusion of newest nonvitamin K antagonist OA (NOACs) (18) , are the main changes that have occurred after the EHS-AF study, which dates back more than 10 years (13).
Thus, ESC member countries deemed it was necessary to update the information on management of AF in Europe. The EORP-AF (EURObservational Research Programme-Atrial Fibrillation) General Pilot Registry was designed with this purpose (19) , and the present analysis specifically addresses the age-related differences in presentation, treatment, and outcomes of patients with AF in that registry.
METHODS
The baseline features and main results from the EORP-AF Registry have been previously published (19) . In brief, the Registry population comprised consecutive inpatients and outpatients with AF evaluated in 70 centers from 9 participating ESC countries. Subjects were screened for eligibility at the time of their presentation to a cardiologist and were 
HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE.
Health-related quality of life was assessed with a selfadministered AF-specific questionnaire (AF-QoL), consisting of 18 items that explore 3 domains of psychological (7 items), physical (8 items), and sexual (3 items) activities. All questions refer to feelings perceived in the preceding month and can be answered on a 5-point Likert scale (from 1, "totally agree," to 5, "totally disagree"), with lower scores indicating greater negative impact of AF on healthrelated quality of life (20) .
STATISTICAL ANALYSIS. In this subanalysis, patients were stratified into $75 years of age ("elderly") and <75 years ("reference") age groups. Continuous and categorical variables were reported as mean AE SD or as median (interquartile range), and as absolute values and related percentages, respectively. Between-group differences were tested with Kruskall-Wallis test and with chi-square test (or Table 1) .
Despite similar mean heart rate and left ventricular ejection fraction (Table 1) , CHF also was more common in the elderly. In older patients, systolic dysfunction, if present, was more often mild-tomoderate (p < 0.0001), with a higher prevalence of CHF with preserved ejection fraction ( Table 1) .
High stroke and bleeding risk were more common among the elderly, as indicated by higher prevalence of CHADS 2 or CHA 2 DS 2 -VASc score $2 and of HAS-BLED score $3 ( Table 1) .
SYMPTOMS AND HEALTH STATUS. Elderly patients were more frequently in European Heart Rhythm Association class I (p < 0.001) and were less often symptomatic (52.4% vs. 64.4%; p < 0.0001), with lower prevalence of palpitations and feelings of fear/ anxiety partially counterbalanced by more frequent dyspnea ( Table 1) . At AF-QoL questionnaire, the total and physical domain scores were lower in the age $75 years group, with similar psychological and sexual activity domains scores.
DIAGNOSTIC PROCEDURES AND TREATMENT STRATEGY.
Transthoracic echocardiography, ECG Holter monitoring, and exercise testing were used significantly less in the elderly subgroup ( Table 2) . 
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A rate-control strategy was more frequently adopted in the elderly, with lower proportions of electrical cardioversion, transcatheter ablation ( Table 2) , and prescription of antiarrhythmic drugs ( Table 3) . Only pacemaker implantation was more common in the elderly ( Table 2) . Among rate-control agents, betablockers were similarly prevalent in both groups, whereas digoxin and nondihydropyridine calciumchannel blockers were more often prescribed to older patients (Table 3) . Diuretics, statins, and aldosterone blockers were also more frequently used in the elderly ( Table 3) .
OA were prescribed less frequently in older patients ( Table 3) , who more frequently received aspirin or clopidogrel, either alone or in combination ( Values are % or mean AE SD. *CHA2DS2-VASc score: low risk, score ¼ 0 in males, score ¼ 1 in females; moderate risk, score ¼ 1 in males; high risk, score $2.
AF ¼ atrial fibrillation; AF-QoL ¼ atrial fibrillation quality-of-life questionnaire; AP ¼ arterial pressure; COPD ¼ chronic obstructive pulmonary disease; EF ¼ left ventricular ejection fraction; EHRA ¼ European Heart Rhythm Association; HFPEF ¼ heart failure with preserved systolic function (EF >45%); TIA ¼ transient ischemic attack.
AF in the Elderly: The EORP-AF Registry the rate-control is the preferred management strategy, and OA are less used, with age in itself and CKD negatively influencing this therapeutic choice.
Conversely, antiplatelet therapy is more frequently prescribed to older individuals, particularly when HAS-BLED score is high. Moreover, a higher proportion of elderly patients have unfavorable outcomes after only 1 year of follow-up.
In the general population, AF increases with age, with a prevalence up to 17.3% above age 75 years (21) .
In our analysis, the proportion of subjects $75 years (33.7%) was remarkably higher than the 12% prevalence of those >80 years of age in the EHS-AF (14) . This difference may result from both the secular trend of ageing of the general population, and an increased awareness of the clinical impact of AF in older cohorts, potentially reducing a referral bias in the EHS-AF. In elderly populations, AF is often a comorbid condition, complicating the course of several acute and chronic diseases (22) . In EORP-AF, patients age $75 years more frequently had a history of CAD, CKD, COPD, hypertension, previous hemorrhagic events, TIA, or valvular heart diseases. Even if ejection fraction and heart rate did not differ by age, older patients more often had CHF, which was frequently caused by CAD, with preserved systolic function.
Accordingly, in the American Heart Association's Get With The Guidelines Heart Failure program, patients with CHF admitted with AF were older and more likely to present with diastolic dysfunction than those in sinus rhythm (23) . Interestingly, our older patients had worse AF-QoL physical domain scores, confirming the major negative impact on functional capacity that AF has at older ages (2).
The general management strategy resulting from the EORP-AF Registry is in keeping with a recent subanalysis of the AFFIRM study, which confirmed that in the elderly a rate-control strategy may be associated with reduced mortality and hospitalizations, compared with a rhythm-control approach (24) .
The lower use of diagnostic procedures in our elderly patients is more difficult to explain. This was These observations were further confirmed in the ORBIT-AF Registry, which demonstrated that several factors associated with advanced age (frailty, prior stroke-TIA, CKD, COPD, osteoporosis, or thyroid disease) could be responsible for underprescription of evidence-based therapies (27) .
In the EORP-AF, OA were used less frequently in elderly patients. Nevertheless, compared with the EHS-AF (14) , which was conducted 10 years before, the prescription rate of OA grew substantially, from an overall 67% (14) to about 81%, and this occurred in the older group as well. In the EHS-AF, OA were used in 68% and in 56% of those age 65 to 80 and >80 years (14) , respectively, whereas in the EORP-AF, 76.7% of those age $75 years received OA. However, European clinical practice is not uniform, as shown by the ATA-AF registry enrolling 7,148 patients with AF with a mean age of 77 years, which in recent years found an average OA prescription rate of only 56.2% in subjects with CHADS 2 score $2, with cardiologists performing much better than internists (15) . Similarly, the Loire Valley Atrial Fibrillation Project found that antithrombotic treatment followed guidelines in only 53% of cases (28) .
In our elderly group, age in itself and CKD were inversely associated with the use of OA, whereas a higher HAS-BLED score increased the probability of Values are %. Before/now/planned ¼ before/at/after study enrollment; catheter ablation ¼ any ablation for atrial fibrillation treatment; thyroid hormone level ¼ thyroid hormone level measurement.
ICD ¼ implantable cardioverter-defibrillator.
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an antiplatelet drug prescription. Indeed, this reflects a persistent reluctance to prescribe OA to older patients, poorly justified in view of the demonstration that, compared with aspirin, warfarin is effective and safe even in patients $75 years of age (12) and that, with increasing age, the protective effect of OA against stroke increases, whereas that of aspirin decreases (29). In the ATRIA study cohort, the net clinical benefit of warfarin therapy remarkably increased with increasing age, and was maximal at $85 years of age (11) . Indeed, the perception of an unacceptably high bleeding risk in the elderly may be unfounded. For example, the bleeding incidence in a large group of patients with a median age of 84 years, followed by OA clinics, was as low as with a number-needed-to-treat of 71 (36) . In accordance with findings from the EHS-AF (14), aspirin and clopidogrel, alone or in combination, were more commonly used in our older cohort, despite current guidelines underlining that aspirin is poorly effective in preventing cardioembolic stroke, while being associated with a risk of major bleeding similar to that observed with OA, especially in the elderly (18) .
STUDY LIMITATIONS. We arbitrarily selected an age $75 years to identify our "elderly" group. We cannot exclude that our results could have been different if we had chosen a more advanced age for stratification purposes. This selection bias might, for example, have contributed to having missed the demonstration of a protective effect of OA in our older cohort, whose worse 1-year prognosis was in fact, at multivariable analysis, associated only with age and several comorbidities (37) .
Patients were enrolled in 70 centers across 9
European countries, which implies a potential intercenter and intercountry variability in the diagnostic and therapeutic strategies for AF. However, data collection confined in European regions might limit Moreover, we have no data on the quality of OA therapy. However, our findings on antithrombotic therapy are qualitatively consistent with those obtained in the previous EHS-AF Registry (14) . Finally, when baseline data were collected, NOACs had not yet received the authorization to be used in some countries.
CONCLUSIONS
The results of the present subanalysis of the EORP-AF Registry show that, in older patients, AF is associated with a more severe comorbidity profile. Rate control is the preferred therapeutic approach, many investigations are underused, and the use of OA is suboptimal in elderly subjects despite their higher CHA 2 DS 2 -VASc score. At follow-up evaluation, the incidence of adverse events is directly related to age and to comorbidities. These findings could be, at least in part, led by "ageism," a practice for which the rates of use of potentially lifesaving and life-enhancing investigations and interventions decline as patients get older (38) , while the elderly are often excluded from randomized controlled trials (39) . Accordingly, the management of patients with AF should change in the different phases of life but it should not be biased by age itself (40). AF in the Elderly: The EORP-AF Registry
